- Conditions
- Growth Hormone Deficiency
- Interventions
- Syntropin
- Drug
- Lead sponsor
- Phage Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 144
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fibromyalgia
- Interventions
- amino acid-based blend
- Dietary Supplement
- Lead sponsor
- Pekarovics, Susan, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neoplasms, Breast
- Interventions
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Placebo, Aromatase inhibitor, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Trastuzumab
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 8
- States / cities
- Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2034
- U.S. locations
- 184
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
- Conditions
- Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
- Interventions
- TransCon hGH
- Drug
- Lead sponsor
- Ascendis Pharma A/S
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
- Conditions
- Acromegaly, Growth Hormone Deficiency, Pituitary Disease
- Interventions
- Recombinant human growth hormone, Saline
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Idiopathic Short Stature
- Interventions
- Genotropin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 3 Years to 10 Years
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 43
- States / cities
- Little Rock, Alaska • Little Rock, Arkansas • Los Angeles, California + 32 more
- Conditions
- Growth Hormone Deficiency (GHD)
- Interventions
- Saizen®
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- US Medical Information, Massachusetts
- Conditions
- Tendinopathy
- Interventions
- Somatropin, Bacteriostatic saline, Progressive exercise program, Patellar tendon biopsy
- Drug · Other · Procedure
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- NAFLD
- Interventions
- somatropin
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Growth Hormone Deficiency
- Interventions
- Somatropin
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 3 Years to 14 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 33
- States / cities
- Little Rock, Arkansas • Orange, California • Sacramento, California + 28 more
- Conditions
- Anorexia Nervosa, Osteopenia, Osteoporosis, Eating Disorders
- Interventions
- Recombinant Human Growth Hormone, Placebo for Recombinant Human Growth Hormone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 45 Years · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Growth Hormone Deficiency
- Interventions
- Somatropin
- Drug
- Lead sponsor
- Altus Pharmaceuticals
- Industry
- Eligibility
- 3 Years to 13 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Orlando, Florida • Springfield, Massachusetts + 7 more
- Conditions
- Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
- Interventions
- asparaginase, daunorubicin hydrochloride, fludarabine phosphate, therapeutic hydrocortisone, allogeneic bone marrow transplantation, 3-dimensional conformal radiation therapy, filgrastim, cytarabine, idarubicin, dexamethasone, thioguanine, etoposide, methotrexate, cyclophosphamide, aldesleukin, busulfan
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Female Infertility Due to Diminished Ovarian Reserve
- Interventions
- Human Growth Hormone, Follicle Stimulating Hormone
- Drug
- Lead sponsor
- Center for Human Reproduction
- Other
- Eligibility
- 18 Years to 44 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypothyroidism
- Interventions
- Growth hormone, Growth hormone treatment and puberty
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Growth Hormone Deficiency
- Interventions
- Somavaratan
- Drug
- Lead sponsor
- Versartis Inc.
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Menlo Park, California
- Conditions
- Growth Hormone Deficiency, Dwarfism
- Interventions
- Dextromethorphan and Caffeine
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 4 Years to 14 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 4
- States / cities
- San Diego, California • Louisville, Kentucky • Kansas City, Missouri + 1 more
- Conditions
- Osteoporosis Pseudoglioma Syndrome
- Interventions
- Human recombinant growth hormone
- Biological
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 4 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hypopituitarism, Hypogonadism, Growth Hormone Deficiency
- Interventions
- Testosterone plus somatropin, testosterone
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Insulin-like Growth Factor-1 Deficiency
- Interventions
- NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Burns, Growth Hormone Treatment
- Interventions
- Somatropin, 0.09% Saline Solution
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Osteoarthritis, Knee
- Interventions
- Recombinant human growth hormone
- Drug
- Lead sponsor
- John Sledge
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Growth Hormone Disorder, Adult Growth Hormone Deficiency
- Interventions
- somapacitan, somatropin, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 23 Years to 79 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 23 more